BioSpace News Archive

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced a new social media campaign designed to raise awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

Elite Pharmaceuticals, Inc. today reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites.

Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company’s commitment to making genetic testing more accessible and equitable for all patient populations.

Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its voting common stock at a price to the public of $4.00 per share.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI) today announced the pricing of an underwritten public offering of 4,761,905 shares of its common stock at a public offering price of $21.00 per share, before underwriting discounts and commissions.

Collegium Pharmaceutical, Inc. announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.